(Updates with CVS Health's reply in the third paragraph.)
A federal judge in Missouri declined Tuesday to accept the request of pharmacy benefit managers to enjoin the Federal Trade Commission's in-house case alleging they systematically preferred high-list-price insulin products in violation of the FTC Act.
The complaint, originally filed last November by CVS Health's (CVS) CVS Caremark, UnitedHealth Group's (UNH) Optum Rx and Cigna Group's (CI) Express Scripts, called the FTC's administrative proceeding unconstitutional and sought an injunction to stop it.
"Drugmakers alone set the price of insulin, but the FTC has already demonstrated it is not interested in considering our full perspective on this topic," a CVS spokesperson told MT Newswires via email. "We will continue to fight this unfair and unconstitutional proceeding."
UnitedHealth and Cigna did not immediately reply to requests for comment.
Price: 66.32, Change: +0.75, Percent Change: +1.14
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。